Which patients with IDH-mutant glioma should receive an isocitrate dehydrogenase (IDH) inhibitor? A top neurosurgeon weighs in.

Credit available for this activity expires: 6/9/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002598?ecd=bdc_podcast_libsyn_mscpedu